9571357

Source:http://linkedlifedata.com/resource/pubmed/id/9571357

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0005330, umls-concept:C0007222, umls-concept:C0007226, umls-concept:C0011847, umls-concept:C0011860, umls-concept:C0562547, umls-concept:C0599724, umls-concept:C0679698, umls-concept:C1274040, umls-concept:C1553269, umls-concept:C2603343
pubmed:issue	4
pubmed:dateCreated	1998-6-16
pubmed:abstractText	To determine whether serum lipid intervention, in addition to conventional diabetes treatment, could alter cardiovascular outcomes in type 2 diabetes.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/7805975
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Bezafibrate, http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol, http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol, HDL, http://linkedlifedata.com/resource/pubmed/chemical/Fibrinogen, http://linkedlifedata.com/resource/pubmed/chemical/Hypolipidemic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Lipids, http://linkedlifedata.com/resource/pubmed/chemical/Lipoproteins, http://linkedlifedata.com/resource/pubmed/chemical/Placebos, http://linkedlifedata.com/resource/pubmed/chemical/Triglycerides
pubmed:status	MEDLINE
pubmed:month	Apr
pubmed:issn	0149-5992
pubmed:author	pubmed-author:DhanjilSS, pubmed-author:DiamondJ RJR, pubmed-author:ElkelesR SRS, pubmed-author:FeherM DMD, pubmed-author:MahmoodSS, pubmed-author:MatherHH, pubmed-author:NicolaidesA NAN, pubmed-author:PoulterCC, pubmed-author:RichmondWW, pubmed-author:SharpPP
pubmed:issnType	Print
pubmed:volume	21
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	641-8
pubmed:dateRevised	2010-11-18
pubmed:meshHeading	pubmed-meshheading:9571357-Adult, pubmed-meshheading:9571357-Aged, pubmed-meshheading:9571357-Bezafibrate, pubmed-meshheading:9571357-Carotid Arteries, pubmed-meshheading:9571357-Cholesterol, pubmed-meshheading:9571357-Cholesterol, HDL, pubmed-meshheading:9571357-Coronary Disease, pubmed-meshheading:9571357-Diabetes Mellitus, Type 2, pubmed-meshheading:9571357-Diabetic Angiopathies, pubmed-meshheading:9571357-Double-Blind Method, pubmed-meshheading:9571357-Electrocardiography, pubmed-meshheading:9571357-Exercise Test, pubmed-meshheading:9571357-Female, pubmed-meshheading:9571357-Femoral Artery, pubmed-meshheading:9571357-Fibrinogen, pubmed-meshheading:9571357-Follow-Up Studies, pubmed-meshheading:9571357-Humans, pubmed-meshheading:9571357-Hypolipidemic Agents, pubmed-meshheading:9571357-Lipids, pubmed-meshheading:9571357-Lipoproteins, pubmed-meshheading:9571357-Male, pubmed-meshheading:9571357-Middle Aged, pubmed-meshheading:9571357-Placebos, pubmed-meshheading:9571357-Time Factors, pubmed-meshheading:9571357-Triglycerides
pubmed:year	1998
pubmed:articleTitle	Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study.
pubmed:affiliation	St. Mary's Hospital, London, U.K.
pubmed:publicationType	Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study